Vascular Endothelial Growth Factor News and Research RSS Feed - Vascular Endothelial Growth Factor News and Research

Anti-VEGF therapy benefits in wet AMD not sustained

Anti-VEGF therapy benefits in wet AMD not sustained

Real-world experience of anti-vascular endothelial growth factor therapy for patients with wet age-related macular degeneration suggests that initial improvements in visual acuity are not maintained over time. [More]
No added benefit with pazopanib over ranibizumab for neovascular AMD

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate. [More]

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Researchers have found three factors that could identify which patients with retinal angiomatous proliferation receiving anti-vascular endothelial growth factor treatment are likely to develop geographic atrophy. [More]

Trained nurses administer AMD treatments as safely and effectively as doctors

Nurses trained to deliver eye injections for patients with the wet form of age-related macular degeneration (AMD) administered the treatments as safely and effectively as doctors, according to a new study. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases. [More]
Amniotic stem cells promote growth of functional blood vessels in healing hydrogels

Amniotic stem cells promote growth of functional blood vessels in healing hydrogels

Rice University and Texas Children's Hospital scientists are using stem cells from amniotic fluid to promote the growth of robust, functional blood vessels in healing hydrogels. [More]
IMDC prognostic model valid in second-line RCC therapy

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology. [More]
Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate. [More]
Discovery may lead to new potential treatment for drug-resistant melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments. [More]
Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced. [More]
Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. [More]
Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers from the Eaton-Peabody Laboratories of Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology Program in Speech and Hearing Bioscience and Technology have revealed new understanding of the pathobiology behind a head and neck tumor that may someday lead to new methods of targeted drug therapy. [More]
Eight clinical researchers selected as finalists for Outstanding Investigator Award at Cardiology 2015

Eight clinical researchers selected as finalists for Outstanding Investigator Award at Cardiology 2015

Pediatric cardiology researchers and clinicians from numerous centers from around the world are gathering at the Cardiology 2015: the 18th Annual Update on Pediatric and Congenital Cardiovascular Disease conference, sponsored by The Children's Hospital of Philadelphia and Phoenix Children's Hospital on Feb. 11 to Feb. 15 in Scottsdale, Ariz. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Omega-3 could supplement anti-VEGF treatment in AMD

Omega-3 could supplement anti-VEGF treatment in AMD

Pilot study findings suggest that taking omega-3 fatty acid supplements could increase the efficacy or reduce the needed frequency of anti-vascular endothelial growth factor treatment in patients with exudative age-related macular degeneration. [More]
Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre may predict visual outcome in diabetic macular oedema patients given the anti-vascular endothelial growth factor monoclonal antibody ranibizumab, a pilot study suggests. [More]

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology. [More]
Advertisement
Advertisement